Pharmacoeconomics Evaluation of Insulin Degludec in the Treatment of Type 1 and Type 2 Diabetes Mellitus / 中国药房
China Pharmacy
;
(12): 4041-4046, 2016.
Artículo
en Chino
| WPRIM
| ID: wpr-502997
ABSTRACT
OBJECTIVE:
To systematically review the cost-effectiveness of insulin degludec(IDeg)in the treatment of type 1 diabetes mellitus(T1DM)and type 2 diabetes mellitus(T2DM).METHODS:
A systematic review of literatures was conducted via PubMed,EMBase,The Cochrane Library,CNKI,Wanfang Data,VIP,IDF,ISPOR,ADA and EASD from the inception to Janu-ary 2016,to identify pharmacoeconomics evaluation literatures and non-economic studies related to IDeg in the treatment of T1DM and T2DM,compared with other basic insulin [insulin glargine(IGlar),insulin detemir(IDet),neutral protamine hagedom insulin (NPH)].RESULTS:
A total of 8 studies were included and all of them were carried out in European countries. In the short-term (one year),IDeg was more economical when compared with other basic insulin in patients with T1DM. The studies related to the long-term treatment of T1DM demonstrated different conclusions,but most of studies came to a conclusion that IDeg had good cost-effectiveness. For patients with T2DM,all of the studies demonstrated that IDeg was cost-effectiveness compared with IGlar.CONCLUSIONS:
Compared with other basic insulin,IDeg can improve therapeutic efficacy and the quality of life,as well as re-duce the cost of ADR as hypoglycaemia. IDeg is a dominant or cost-effective treatment opinion.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Evaluación Económica en Salud
Idioma:
Chino
Revista:
China Pharmacy
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS